Shilpa Medicare Limited (NSE:SHILPAMED) — Market Cap & Net Worth

$1.15 Billion USD  · Rs106.71 Billion INR  · Rank #8447

Market Cap & Net Worth: Shilpa Medicare Limited (SHILPAMED)

Shilpa Medicare Limited (NSE:SHILPAMED) has a market capitalization of $1.15 Billion (Rs106.71 Billion) as of June 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #8447 globally and #408 in its home market, demonstrating a -2.36% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shilpa Medicare Limited's stock price Rs545.60 by its total outstanding shares 195581816 (195.58 Million). Review Shilpa Medicare Limited balance sheet liabilities to assess the company's total debt and financial obligations.

Shilpa Medicare Limited Market Cap History: 2015 to 2026

Shilpa Medicare Limited's market capitalization history from 2015 to 2026. Data shows growth from $1.04 Billion to $1.15 Billion (1.35% CAGR).

Index Memberships

Shilpa Medicare Limited is a constituent of 2 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NIFTY MICROCAP 250
NIFTYMICROCAP250
$149.83 Billion 0.77% #44 of 250
NIFTY TOTAL MARKET
NIFTYTOTALMKT
$3.24 Trillion 0.04% #346 of 750

Weight: Shilpa Medicare Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Shilpa Medicare Limited Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Shilpa Medicare Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.05x

Shilpa Medicare Limited's market cap is 0.05 times its annual revenue

Industry average: 0.53x Lower than industry average

Latest Price to Earnings (P/E) Ratio

0.87x

Shilpa Medicare Limited's market cap is 0.87 times its annual earnings

Industry average: 0.02x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $1.44 Billion $6.38 Billion $1.08 Billion 0.23x 1.33x
2017 $1.29 Billion $7.30 Billion $1.08 Billion 0.18x 1.20x
2018 $806.26 Million $7.49 Billion $1.05 Billion 0.11x 0.77x
2019 $592.10 Million $7.01 Billion $1.12 Billion 0.08x 0.53x
2020 $947.93 Million $8.99 Billion $1.56 Billion 0.11x 0.61x
2021 $1.13 Billion $9.00 Billion $1.48 Billion 0.13x 0.76x
2022 $588.75 Million $11.40 Billion $606.62 Million 0.05x 0.97x
2023 $698.63 Million $10.43 Billion -$325.33 Million 0.07x N/A
2024 $1.72 Billion $11.53 Billion $318.74 Million 0.15x 5.41x
2025 $679.28 Million $12.86 Billion $782.93 Million 0.05x 0.87x

Competitor Companies of SHILPAMED by Market Capitalization

Companies near Shilpa Medicare Limited in the global market cap rankings as of June 19, 2026.

Key companies related to Shilpa Medicare Limited by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#515 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#555 GALDERMA GROUP AG NYSE:GALDY $48.78 Billion $42.94
#601 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $45.20 Billion CN¥48.42
#627 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €13.30

Shilpa Medicare Limited Historical Marketcap From 2015 to 2026

Between 2015 and today, Shilpa Medicare Limited's market cap moved from $1.04 Billion to $ 1.15 Billion, with a yearly change of 1.35%.

Year Market Cap Change (%)
2026 Rs1.15 Billion +69.89%
2025 Rs679.28 Million -60.62%
2024 Rs1.72 Billion +146.90%
2023 Rs698.63 Million +18.66%
2022 Rs588.75 Million -47.83%
2021 Rs1.13 Billion +19.06%
2020 Rs947.93 Million +60.10%
2019 Rs592.10 Million -26.56%
2018 Rs806.26 Million -37.62%
2017 Rs1.29 Billion -10.31%
2016 Rs1.44 Billion +38.89%
2015 Rs1.04 Billion --

End of Day Market Cap According to Different Sources

On Jun 19th, 2026 the market cap of Shilpa Medicare Limited was reported to be:

Source Market Cap
Yahoo Finance $1.15 Billion USD
MoneyControl $1.15 Billion USD
MarketWatch $1.15 Billion USD
marketcap.company $1.15 Billion USD
Reuters $1.15 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Shilpa Medicare Limited

NSE:SHILPAMED India Drug Manufacturers - Specialty & Generic
Market Cap
$1.15 Billion
Rs106.71 Billion INR
Market Cap Rank
#8447 Global
#408 in India
Share Price
Rs545.60
Change (1 day)
-4.68%
52-Week Range
Rs267.00 - Rs932.85
All Time High
Rs985.80
About

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, … Read more